Table 2.
Adverse events
| Adverse event* | Grade 2 | Grade 3 | Grade 4 | Total |
|---|---|---|---|---|
| Alkaline phosphatase increased | – | 1 | – | 1 (11%) |
| Anemia | – | 2 | 1 | 3 (33%) |
| Anorexia | 1 | – | – | 1 (11%) |
| Fatigue | 2 | – | – | 2 (22%) |
| Fever | 1 | – | – | 1 (11%) |
| Lymphocyte count decreased | 4 | 1 | – | 5 (56%) |
| Nausea | 2 | – | – | 2 (22%) |
| Neutrophil count decreased | 4 | 2 | – | 6 (67%) |
| Platelet count decreased | 3 | – | 1 | 4 (44%) |
| Tinnitus | 1 | – | – | 1 (11%) |
| Weight loss | 1 | – | – | 1 (11%) |
| White blood cell decreased | 5 | 1 | – | 6 (67%) |
*Worst grade (≥ grade 2) per patient that was at least possibly related to study agent is reported